ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 82 filers reported holding ARBUTUS BIOPHARMA CORP in Q4 2020. The put-call ratio across all filers is 1.54 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $709,197 | -8.3% | 349,358 | +4.0% | 0.00% | – |
| Q2 2023 | $772,968 | -17.4% | 336,073 | +8.8% | 0.00% | – |
| Q1 2023 | $936,176 | +31.6% | 308,969 | +1.2% | 0.00% | – |
| Q4 2022 | $711,302 | +29.6% | 305,280 | +6.2% | 0.00% | – |
| Q3 2022 | $549,000 | -29.7% | 287,419 | -0.2% | 0.00% | – |
| Q2 2022 | $781,000 | +9.2% | 287,954 | +20.1% | 0.00% | – |
| Q1 2022 | $715,000 | -12.3% | 239,713 | +14.5% | 0.00% | – |
| Q4 2021 | $815,000 | -9.3% | 209,375 | 0.0% | 0.00% | – |
| Q3 2021 | $899,000 | +59.1% | 209,375 | +12.3% | 0.00% | – |
| Q2 2021 | $565,000 | +707.1% | 186,468 | +791.7% | 0.00% | – |
| Q1 2021 | $70,000 | -6.7% | 20,912 | 0.0% | 0.00% | – |
| Q4 2020 | $75,000 | -27.9% | 20,912 | -36.5% | 0.00% | – |
| Q3 2020 | $104,000 | -55.9% | 32,912 | -50.1% | 0.00% | – |
| Q1 2019 | $236,000 | -6.7% | 65,900 | 0.0% | 0.00% | – |
| Q4 2018 | $253,000 | -59.4% | 65,900 | 0.0% | 0.00% | – |
| Q3 2018 | $623,000 | +29.3% | 65,900 | 0.0% | 0.00% | – |
| Q2 2018 | $482,000 | – | 65,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Whitefort Capital Management, LP | 11,895,477 | $24,147,818 | 12.66% |
| Two Seas Capital LP | 8,280,818 | $16,810,061 | 3.38% |
| FourWorld Capital Management LLC | 1,341,907 | $2,724,071 | 0.51% |
| Tejara Capital Ltd | 180,077 | $365,556 | 0.21% |
| Woodline Partners LP | 4,719,903 | $9,581,403 | 0.11% |
| Hudson Bay Capital Management LP | 8,299,808 | $16,848,610 | 0.07% |
| Kepos Capital LP | 155,691 | $316 | 0.06% |
| Virtus ETF Advisers LLC | 40,040 | $81,281 | 0.05% |
| Centiva Capital, LP | 1,071,705 | $2,175,561 | 0.05% |
| Kades & Cheifetz LLC | 20,000 | $40,600 | 0.03% |